BridgeBio Oncology Therapeutics (BBOT) & The Competition Critical Contrast

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is one of 320 public companies in the “Investment Offices” industry, but how does it compare to its competitors? We will compare BridgeBio Oncology Therapeutics to related businesses based on the strength of its valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Earnings & Valuation

This table compares BridgeBio Oncology Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	-$134.04 million	-4.17
BridgeBio Oncology Therapeutics Competitors	$61.49 million	-$160.87 million	-391.01

BridgeBio Oncology Therapeutics’ competitors have higher revenue, but lower earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 48.4% of shares of all “Investment Offices” companies are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Comparatively, 29.1% of shares of all “Investment Offices” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares BridgeBio Oncology Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
BridgeBio Oncology Therapeutics Competitors	697.12%	-3.34%	-1.94%

Volatility & Risk

BridgeBio Oncology Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, BridgeBio Oncology Therapeutics’ competitors have a beta of 0.41, suggesting that their average stock price is 59% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for BridgeBio Oncology Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1	0	4	0	2.60
BridgeBio Oncology Therapeutics Competitors	329	86	127	2	1.64

BridgeBio Oncology Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 192.40%. As a group, “Investment Offices” companies have a potential upside of 26.91%. Given BridgeBio Oncology Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than its competitors.

Summary

BridgeBio Oncology Therapeutics beats its competitors on 8 of the 13 factors compared.

About BridgeBio Oncology Therapeutics

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.